Bill > SF2645

This bill modifies Minnesota's Formulary Committee regulations to enhance transparency, conflict of interest disclosure, and public participation in pharmaceutical decision-making. Specifically, the bill expands the Formulary Committee's composition to include diverse medical professionals, a representative from the Rare Disease Advisory Council, and consumer representatives, while establishing stricter conflict of interest guidelines. Members must now disclose potential conflicts, which will be publicly posted on the Department of Human Services website, and they can be removed for cause but not for offering differing clinical opinions. The bill also mandates that the Formulary Committee seek expertise from the Rare Disease Advisory Council before making decisions about orphan drugs or prior authorization requirements. Additionally, the bill requires a more robust public comment process, including mandatory public hearings, advance notice of meetings, and public disclosure of comments and analysis related to drug list modifications. The bill extends the Formulary Committee's existence until 2030, increases meeting frequency, provides members with a modest honorarium, and ensures that the committee's activities are subject to open meeting laws while allowing for expert consultation and communication within certain constraints.

Health and Social Services

https://www.revisor.mn.gov/bills/bill.php?b=Senate&f=SF2645&ssn=0&y=2025